Sugi Predict

Sugi Predict / Compounds / SCHEMBL23623293

SCHEMBL23623293

SCHEMBL23623293

CCOc1ccc(F)cc1-c1cc(CNC(=O)c2ccccc2OC(F)(F)F)n[nH]1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MRGPRX1 Q96LB2 2/20 0.43
▸ HCRTR1 O43613 2/20 0.42
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ F2R P25116 1/20 0.40
▸ TSPO P30536 1/20 0.40
▸ KCNK3 O14649 2/20 0.40
▸ KCNK9 Q9NPC2 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ KCNB1 Q14721 1/20 0.39
▸ HCN1 O60741 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623250 0.93 F2R (0.41) HPGDMAPTTSHRHSD17B10MRGPRX1
SCHEMBL23623254 0.91 KCNK3 (0.47) HPGDMAPTHSD17B10MEN1KMT2A
SCHEMBL23623234 0.88 KCNK3 (0.50) F2RKCNK3KCNK9KDM4EALDH1A1
SCHEMBL23623252 0.87 TSHR (0.43) HPGDMAPTTSHRHSD17B10MRGPRX1
SCHEMBL23623347 0.87 MEN1 (0.40) MAPTMEN1KMT2AF2RKCNK3
SCHEMBL23623350 0.83 HSD17B13 (0.40) MAPTF2RKCNK3KCNK9HCN1
SCHEMBL26601342 0.83 AKR1B1 (0.46) KMT2AKCNK3KCNK9POLBHCN1
SCHEMBL23623253 0.83 KCNK3 (0.42) HPGDMAPTF2RKCNK3KCNK9
SCHEMBL23623811 0.83 KCNK3 (0.50) HPGDMAPTHSD17B10MEN1KMT2A
SCHEMBL23623295 0.83 KCNK3 (0.48) HPGDMAPTHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091590-A1 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER BERG LLC (US) 2023-05-25 — — WO disclosed
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2022-01-06 — — US disclosed
US-11091447-B2 UBE2K modulators and methods for their use BERG LLC (US) 2021-08-17 — — US disclosed
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2021-07-15 — — US disclosed
WO-2021138540-A1 POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER BERG LLC (US) 2021-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091447-B2 UBE2K modulators and methods for their use UBE2N, UBE2B, UBE2E1 HPGD 1216/4885MAPT 1520/4885TSHR 4538/4885
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 HPGD 1216/4885MAPT 1520/4885TSHR 4538/4885
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 HPGD 1216/4885MAPT 1520/4885TSHR 4538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.